Detalhe da pesquisa
1.
Kinase Inhibitors FDA-Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities.
Drug Metab Dispos
; 2024 Jan 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38286637
2.
Advances and Challenges in Modeling Cannabidiol Pharmacokinetics and Hepatotoxicity.
Drug Metab Dispos
; 2024 Jan 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38286636
3.
Biotransformation research advances - 2022 year in review.
Drug Metab Rev
; 55(4): 301-342, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37737116
4.
Novel Approaches to Characterize Individual Drug Metabolism and Advance Precision Medicine.
Drug Metab Dispos
; 51(10): 1238-1253, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37419681
5.
Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors.
Circ Res
; 128(12): 1973-1987, 2021 06 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34110908
6.
Vaping additives cannabinoid oil and vitamin E acetate adhere to and damage the human airway epithelium.
J Appl Toxicol
; 43(5): 680-693, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36372912
7.
Biotransformation novel advances - 2021 year in review.
Drug Metab Rev
; 54(3): 207-245, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35815654
8.
Bioactivation and reactivity research advances - 2021 year in review.
Drug Metab Rev
; 54(3): 246-281, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35876116
9.
Cytochromes P450 2C8 and 3A Catalyze the Metabolic Activation of the Tyrosine Kinase Inhibitor Masitinib.
Chem Res Toxicol
; 35(9): 1467-1481, 2022 09 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-36048877
10.
Interindividual Variability in Cytochrome P450 3A and 1A Activity Influences Sunitinib Metabolism and Bioactivation.
Chem Res Toxicol
; 35(5): 792-806, 2022 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35484684
11.
Novel advances in biotransformation and bioactivation research - 2020 year in review.
Drug Metab Rev
; 53(3): 384-433, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33910427
12.
Cytochrome P450-Catalyzed Metabolism of Cannabidiol to the Active Metabolite 7-Hydroxy-Cannabidiol.
Drug Metab Dispos
; 49(10): 882-891, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34330718
13.
Detoxication versus Bioactivation Pathways of Lapatinib In Vitro: UGT1A1 Catalyzes the Hepatic Glucuronidation of Debenzylated Lapatinib.
Drug Metab Dispos
; 49(3): 233-244, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33376146
14.
Novel advances in biotransformation and bioactivation research-2019 year in review.
Drug Metab Rev
; 52(3): 333-365, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32645275
15.
Impact of cytochrome P450 variation on meperidine N-demethylation to the neurotoxic metabolite normeperidine.
Xenobiotica
; 50(2): 209-222, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30902024
16.
Interindividual Variation in CYP3A Activity Influences Lapatinib Bioactivation.
Drug Metab Dispos
; 47(11): 1257-1269, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31492693
17.
HU-331 and Oxidized Cannabidiol Act as Inhibitors of Human Topoisomerase IIα and ß.
Chem Res Toxicol
; 31(2): 137-144, 2018 02 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29272108
18.
Cytochromes P450 1A2 and 3A4 Catalyze the Metabolic Activation of Sunitinib.
Chem Res Toxicol
; 31(7): 570-584, 2018 07 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-29847931
19.
Role of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors.
Int J Mol Sci
; 19(8)2018 Aug 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30103502
20.
Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib.
Drug Metab Dispos
; 44(10): 1584-97, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27450182